GSK beats forecasts, thanks to COVID antibody and Shingrix s...

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021.

Vaccines upstart Curevo has designs on blockbuster GSK franc...

Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and Gla

Look out GSK, Pfizer and BioNTech are coming for Shingrix

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion.

GSK wants to double Shingrix sales, and a new FDA okay could...

The FDA has approved GlaxoSmithKline's shingles vaccine Shingrix for use in people aged under 50 who are immunocompromised – a key step in the UK drugmaker's plan to build the shot into a £

Vaccine sales recover at GSK in Q3, but lockdown fears weigh...

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end

GSK starts 2020 on a high, but warns of tougher times ahead